Search

Pfizer PF-08653944 Safety Trial, Reduced Liver Function

Pfizer registered a Phase 1 clinical trial on ClinicalTrials.gov (NCT07519135) to evaluate the safety and pharmacokinetics of investigational drug PF-08653944 in participants with reduced liver function (hepatic impairment). The single-arm, open-label study aims to characterize how hepatic impairment affects the drug's safety profile and exposure. ClinicalTrials.gov serves as a public registry for clinical studies and does not constitute regulatory approval or review of the investigated product.

NTX-2001 Alcohol Use Disorder Study (NCT07520292)

NLM registered clinical trial NCT07520292, a Phase 1/2 study evaluating NTX-2001 for alcohol use disorder treatment. The trial is sponsored by Newleos Pharma with enrollment managed by Yale University investigators. The study aims to assess safety and efficacy of the investigational product in adult participants.

Ex Vivo Porcine Liver Perfusion, Severe Hepatic Failure (NCT07519005)

ClinicalTrials.gov registered a new clinical study (NCT07519005) titled 'Ex Vivo Porcine Liver Perfusion, Severe Hepatic Failure.' The study will investigate ex vivo liver perfusion using porcine (pig) livers as an experimental approach for treating severe hepatic failure. The trial is registered under ClinicalTrials.gov requirements.

Phase I Pfizer Trial PF-08046033 in NSCLC Melanoma

ClinicalTrials.gov registered a Phase I clinical trial sponsored by Pfizer evaluating investigational drug PF-08046033 in patients with Non-Small Cell Lung Cancer (NSCLC) and Melanoma. The trial, identified as NCT07519655, is an early-phase oncology study assessing safety, tolerability, and pharmacokinetics in cancer patients.

CD19/CD22 CAR T Cell Treatment for High-Risk Pediatric Acute Lymphoblastic Leukemia

The USPTO published patent application US20260097122A1 for CD19/CD22 chimeric antigen receptor (CAR) T-cell products and methods for treating high-risk or relapsed CD19+ or CD22+ haematological malignancies, specifically pediatric acute lymphoblastic leukemia. The application was filed on May 10, 2023, under application number 18862269. Inventors include Martin Pulé, Persis Amrolia, and Sara Ghorashian.

Oncolytic Vaccinia Viruses and Recombinant Viruses and Methods of Use Thereof

The USPTO published patent application US20260097116A1 by ViroMissile, Inc. covering clonal strains of vaccinia virus engineered as oncolytic virus therapies for treating cancer. The application includes claims for recombinant vaccinia viruses with inactivating mutations and heterologous gene products, pharmaceutical compositions, and methods of use for anti-tumor therapy.

Fluorescent Probe Compounds for Tumor-Targeted Imaging and Synthesis Methods

USPTO published patent application US20260097137A1 by Hebei Medical University for fluorescent probe compounds utilizing a pyrrolo[2,3-d]pyrimidine core structure conjugated to a fluorescent dye for tumor-targeted imaging. The probes demonstrate high affinity and selectivity for tumor cells, rapid clearance from normal tissues, and prolonged retention at tumor sites. The invention enables in vitro and in vivo tracking, receptor affinity studies, and intraoperative navigation applications.

Epigenetic Editing Tool for Targeting Hepatitis B Virus Gene

USPTO published patent application US20260097133A1 for an epigenetic editing tool targeting hepatitis B virus genes, filed by inventors Wenbo Peng, Junzheng Zhao, Shaoshuai Mao, Leilei Wu, Di Sun, Ruimin Lv, Ying Zang, and Junjian Liu on December 4, 2025. The application covers compositions and methods for epigenetic modification of HBV genes for therapeutic use in biomedicine.

Rapid Conjugate Vaccine Manufacturing Method, Inventprise

Rapid Conjugate Vaccine Manufacturing Method, Inventprise

GIP/GLP-1 Dual Agonist Formulations for Metabolic and Liver Disorders

The USPTO published patent application US20260097126A1 disclosing pharmaceutical formulations of small molecule GIP/GLP-1 dual receptor agonists for treating metabolic and liver disorders. The application (No. 18995773) was filed on July 18, 2023, by inventors Brian Lian, Geoffrey E. Barker, Maureen Barnes, Brahmachary Enugurthi, and Jake Gonzalez. The formulations include compounds classified under CPC codes A61K 47/548, A61K 9/0019, and others, with therapeutic applications targeting A61P 3/06 (metabolic disorders).